OHR Pharmaceutical Inc.

Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA

Download PDF

NEW YORK, April 27, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Conference, taking place May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.

Poster Details:  
Title: Sustained Retinal Concentrations of OHR3031 Achieved with Intravitreal Injection of a Biodegradable Microparticle Formulation to Rabbits
Poster #: C0059
Authors: Modi M, Wirostko W, Jennings R, Reddy L, Malavia N, Simonian A, Szinai I, Stoller G
Date: Sunday, May 1, 2016
Time: 1:30pm to 3:15pm Pacific Time
Title: CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti-VEGF therapy and topical Squalamine lactate ophthalmic solution
Poster#: A0324
Authors: Brown D, Ingerman A, Shearn S, Slakter J
Date: Wednesday, May 4, 2016
Time: 8:30am to 10:15am Pacific Time

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, squalamine lactate ophthalmic solution, 0.2% (“Squalamine,” also known as OHR-102), is currently being studied using an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

Ohr Pharmaceutical Inc.
Investor Relations

LifeSci Advisors, LLC
Michael Wood

Primary Logo

Source: Ohr Pharmaceutical, Inc.